Karthik Kuppusamy - Jul 30, 2025 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)

Role
SVP, Clinical Solutions
Signature
Sean D. Mersten, Attorney in Fact for Karthik Kuppusamy
Stock symbol
DGX
Transactions as of
Jul 30, 2025
Transactions value $
-$1,759,931
Form type
4
Date filed
8/1/2025, 04:37 PM
Previous filing
Jul 25, 2025
Next filing
Aug 15, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KUPPUSAMY KARTHIK SVP, Clinical Solutions 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS Sean D. Mersten, Attorney in Fact for Karthik Kuppusamy 2025-08-01 0001955217

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DGX Common Stock Options Exercise $264K +3.05K +28.56% $86.63 13.7K Jul 30, 2025 Direct F1
transaction DGX Common Stock Sale -$510K -3.05K -22.22% $167.40 10.7K Jul 30, 2025 Direct F1
transaction DGX Common Stock Options Exercise $586K +5.22K +49.01% $112.17 15.9K Jul 30, 2025 Direct F1
transaction DGX Common Stock Sale -$874K -5.22K -32.89% $167.40 10.7K Jul 30, 2025 Direct F1
transaction DGX Common Stock Sale -$376K -2.21K -20.73% $170.00 8.45K Jul 31, 2025 Direct F1
holding DGX Common Stock 358 Jul 30, 2025 By Trust
holding DGX Common Stock 1.63K Jul 30, 2025 401(k) F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise -$264K -3.05K -100% $86.63 0 Jul 30, 2025 Common Stock 3.05K $86.63 Direct F1, F3
transaction DGX Non-Qualifed Stock Option (right to buy) Options Exercise -$586K -5.22K -100% $112.17 0 Jul 30, 2025 Common Stock 5.22K $112.17 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
F3 The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022.
F4 The options vested in three annual installments beginning with the first on February 18, 2021, the second on February 18, 2022 and the final on February 18, 2023.